Limits...
Serum atrial natriuretic peptide: a suspected biomarker of breast cancer

View Article: PubMed Central - PubMed

ABSTRACT

Aim of the study: To assess serum levels of ANP in breast cancer female patients and its relationship to metastasis and some clinical parameters among those patients.

Material and methods: One hundred breast cancer patients with and without metastasis along with 20 healthy closely matched controls, were enrolled in the present cross sectional study. Background: To assess the serum levels of atrial natriuretic peptide in breast cancer Serum levels of ANP were assessed using ELISA.

Results: Mean serum levels of ANP breast cancer patients (13.9 ±10.1 ng/ml) were significantly elevated compared to healthy control group (2.2 ±1.3 ng/ml) (p < 0.001). The metastatic breast cancer patients showed significant elevated ANP levels (17.1 ±8.9 ng/ml) compared to non-metastatic group (6.4 ±8.8 ng/ml) p < 0.001. Within the metastatic group significant difference was detected between de novo metastatic, under follow-up, under hormonal control and locally advanced group (p = 0.007).

Conclusions: This study showed significant elevated levels of ANP in the serum of metastatic breast cancer patients compared to non-metastatic patients. Within the metastatic group the lowest levels were detected in metastatic breast Cancer under hormonal treatment either tamoxifen or aromatase inhibitor.

No MeSH data available.


ROC curve of ANP for discrimination between cases and controls
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5385479&req=5

f0002: ROC curve of ANP for discrimination between cases and controls

Mentions: One-way ANOVA within the four groups of metastatic breast cancer patients using the serum ANP as the dependent variable revealed that there were significant differences in ANP levels between groups (p = 0.007) (Table 4, Fig. 2).


Serum atrial natriuretic peptide: a suspected biomarker of breast cancer
ROC curve of ANP for discrimination between cases and controls
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5385479&req=5

f0002: ROC curve of ANP for discrimination between cases and controls
Mentions: One-way ANOVA within the four groups of metastatic breast cancer patients using the serum ANP as the dependent variable revealed that there were significant differences in ANP levels between groups (p = 0.007) (Table 4, Fig. 2).

View Article: PubMed Central - PubMed

ABSTRACT

Aim of the study: To assess serum levels of ANP in breast cancer female patients and its relationship to metastasis and some clinical parameters among those patients.

Material and methods: One hundred breast cancer patients with and without metastasis along with 20 healthy closely matched controls, were enrolled in the present cross sectional study. Background: To assess the serum levels of atrial natriuretic peptide in breast cancer Serum levels of ANP were assessed using ELISA.

Results: Mean serum levels of ANP breast cancer patients (13.9 ±10.1 ng/ml) were significantly elevated compared to healthy control group (2.2 ±1.3 ng/ml) (p < 0.001). The metastatic breast cancer patients showed significant elevated ANP levels (17.1 ±8.9 ng/ml) compared to non-metastatic group (6.4 ±8.8 ng/ml) p < 0.001. Within the metastatic group significant difference was detected between de novo metastatic, under follow-up, under hormonal control and locally advanced group (p = 0.007).

Conclusions: This study showed significant elevated levels of ANP in the serum of metastatic breast cancer patients compared to non-metastatic patients. Within the metastatic group the lowest levels were detected in metastatic breast Cancer under hormonal treatment either tamoxifen or aromatase inhibitor.

No MeSH data available.